Oxford Coronavirus Vaccine

The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.

Oxford University scientists said on Tuesday they would evaluate the effects of new coronavirus variants on pregnant women and newborns, as well as COVID-19 vaccination effects on complications during pregnancy and after birth.

The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.

A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.

Two-dose COVID-19 vaccine regimens do not induce enough neutralising antibodies against the Omicron coronavirus variant, British scientists found, indicating that increased infections in those previously infected or vaccinated may be likely.

There's no evidence existing vaccines won't provide some protection against the omicron variant, the University of Oxford said as scientists scramble to assess the new Covid-19 mutation.

COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.

A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.

Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca coronavirus vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.

The very rare blood clots that can be caused by the Oxford/AstraZeneca coronavirus vaccine can be aggressive and deadly but is very rare, leading scientists have concluded in the findings of the first study of its kind on Thursday.

The highly transmissible Delta variant of coronavirus has rendered the prospect of herd immunity, where the majority of a country's population becomes immune to a virus, difficult, the head of the UK's Oxford Vaccine Group has warned.

Two doses of COVID-19 vaccines are "highly effective" in preventing hospital admission with the Delta variant, Public Health England said on Monday.

Britain is in talks with Oxford and AstraZeneca for additional doses of their COVID-19 vaccine that has been modified to better target the "beta" coronavirus variant first identified in South Africa, and it will fund trials of the shots.

A single dose of either the Oxford/AstraZeneca or Pfizer/BioNTech vaccines, currently being administered in the UK, cut the rate of coronavirus infections by around 65 per cent, according to a new UK study on Friday.

The risk of rare blood clotting following the COVID-19 infection is around 100 times greater than normal, several times higher than it is post-vaccination or following influenza, according to a new University of Oxford study published on Thursday.

The Supreme Court will hear a petition on a rare side-effect associated with the COVID vaccine developed jointly by British pharma giant AstraZeneca and Oxford University, manufactured by the Serum Institute of India and sold in India as Covishield.

Oxford University scientists said on Tuesday they would evaluate the effects of new coronavirus variants on pregnant women and newborns, as well as COVID-19 vaccination effects on complications during pregnancy and after birth.

The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.

A three-dose course of AstraZeneca's COVID-19 vaccine is effective against the Omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.

Two-dose COVID-19 vaccine regimens do not induce enough neutralising antibodies against the Omicron coronavirus variant, British scientists found, indicating that increased infections in those previously infected or vaccinated may be likely.

There's no evidence existing vaccines won't provide some protection against the omicron variant, the University of Oxford said as scientists scramble to assess the new Covid-19 mutation.

COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.

A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.

Protection against COVID-19 offered by two doses of the Pfizer/BioNTech and the Oxford/AstraZeneca coronavirus vaccines begins to fade within six months, underscoring the need for booster shots, according to researchers in Britain.

The very rare blood clots that can be caused by the Oxford/AstraZeneca coronavirus vaccine can be aggressive and deadly but is very rare, leading scientists have concluded in the findings of the first study of its kind on Thursday.

The highly transmissible Delta variant of coronavirus has rendered the prospect of herd immunity, where the majority of a country's population becomes immune to a virus, difficult, the head of the UK's Oxford Vaccine Group has warned.

Two doses of COVID-19 vaccines are "highly effective" in preventing hospital admission with the Delta variant, Public Health England said on Monday.

Britain is in talks with Oxford and AstraZeneca for additional doses of their COVID-19 vaccine that has been modified to better target the "beta" coronavirus variant first identified in South Africa, and it will fund trials of the shots.

A single dose of either the Oxford/AstraZeneca or Pfizer/BioNTech vaccines, currently being administered in the UK, cut the rate of coronavirus infections by around 65 per cent, according to a new UK study on Friday.

The risk of rare blood clotting following the COVID-19 infection is around 100 times greater than normal, several times higher than it is post-vaccination or following influenza, according to a new University of Oxford study published on Thursday.